Retatrutide: Side Effects Reported in Studies
This page collects the adverse effects of retatrutide that the authors of published studies described. It rests on randomized phase 1, 2 and 3 trials in adults with obesity or type 2 diabetes [1][2][3][4][6], plus one systematic review [7]. In those trials retatrutide was an investigational drug given by weekly subcutaneous injection. The page is a research summary and gives no advice on use.
Summary
- Gastrointestinal effects were reported most often: nausea, diarrhea, vomiting and constipation. Their frequency depended on dose, and the authors described them mostly as mild to moderate [1][2][4][5].
- In the phase 3 trial TRIUMPH-2 (80 weeks), diarrhea occurred in 27-34% of participants on retatrutide versus 13% on placebo, and nausea in 14-28% versus 8% [3].
- Hypotension and dysesthesia were reported more often on retatrutide than on placebo in that trial [3].
- In phase 2, a dose-dependent increase in heart rate peaked at week 24 and declined afterwards [1].
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Diarrhea | TRIUMPH-2: adults with obesity and type 2 diabetes, 80 weeks, versus placebo | 27% (4 mg), 34% (9 mg), 34% (12 mg) vs 13% with placebo | [3] |
| Nausea | TRIUMPH-2 | 14% (4 mg), 21% (9 mg), 28% (12 mg) vs 8% with placebo | [3] |
| Hypotension | TRIUMPH-2 | 1% (4 mg), 5% (9 mg), 6% (12 mg) vs under 1% with placebo | [3] |
| Dysesthesia | TRIUMPH-2 | 4% (4 mg), 6% (9 mg), 7% (12 mg) vs 1% with placebo | [3] |
| Permanent discontinuation due to adverse events or death | TRIUMPH-2 | 4% (4 mg), 12% (9 mg), 8% (12 mg) vs 5% with placebo | [3] |
| Gastrointestinal events | TRIUMPH-1: 2339 adults with obesity without diabetes, 80 weeks | Named the most common adverse events; frequencies are not given in the abstract | [4] |
| Gastrointestinal events, mostly mild to moderate | TRANSCEND-T2D-1: 537 adults with type 2 diabetes, 40 weeks | Subsided over time; discontinuation due to adverse events 2-5% on retatrutide vs 0% on placebo | [5] |
| Nausea, diarrhea, vomiting, constipation | Phase 2, type 2 diabetes, up to 36 weeks, 190 participants on retatrutide | 35% of participants had gastrointestinal events collectively, not each symptom individually: from 13% at 0.5 mg to 50% at 8 mg with fast escalation; 13% on placebo, 35% on dulaglutide | [2] |
| Gastrointestinal events | Phase 2, obesity, 338 adults, 48 weeks | Dose-related, mostly mild to moderate; a lower starting dose (2 mg instead of 4 mg) partly reduced them | [1] |
| Increase in heart rate | Phase 2, obesity, 48 weeks | Dose-dependent, peak at week 24, then a decline | [1] |
| Any treatment-emergent adverse event | Phase 1b, type 2 diabetes, 72 participants, 12 weeks | 63% (33/52) on retatrutide vs 54% (8/15) on placebo and 60% (3/5) on dulaglutide; gastrointestinal disorders were most frequent | [6] |
| Any adverse event | As reported in the systematic-review abstract: 3 randomized trials, 878 participants | Relative risk 1.11 versus placebo, difference not significant (p = 0.24) | [7] |
What the effects depended on
In phase 2 the authors linked gastrointestinal events to the retatrutide dose and the escalation scheme: a lower starting dose (2 mg instead of 4 mg) partly mitigated them [1]. In the type 2 diabetes trial the share of participants with such events was highest at 8 mg with fast escalation (50%) [2]. In TRIUMPH-2, diarrhea and nausea were more frequent at higher doses, and discontinuation was more frequent at 9 mg and 12 mg than at 4 mg [3]. Dose schedules are covered in the retatrutide dosing reference.
Serious and rare events
In TRIUMPH-2, seven participants died: two at 4 mg, three at 9 mg, one at 12 mg and one on placebo. The investigators judged all of them unrelated to the study drug [3]. TRANSCEND-T2D-1 recorded two deaths, both at 4 mg and also judged unrelated, and no severe hypoglycemia [5]. The phase 2 type 2 diabetes trial had no severe hypoglycemia and no deaths [2]. The abstracts reviewed give no frequencies for pancreatitis, gallbladder disease or other rare events, so this page has no figures for them.
Limits of the evidence
All the trials mentioned were funded by the developer, and the longest ran 80 weeks [1][2][3][4][5][6]. The systematic-review abstract reports three trials with 878 participants and calls for longer trials [7]. A nonsignificant adverse-event difference does not establish equivalent safety. The sources reviewed contain no data on long-term safety beyond these durations. The data describe a drug given under trial protocols. One case report describes marked nausea after injections of a product claimed to be retatrutide whose contents and dosing were unconfirmed. Symptoms resolved within a week after admission with supportive care [8]. A single case gives no frequency and does not establish retatrutide-specific causality; trial results cannot automatically transfer to products of unconfirmed composition.
FAQ
Which retatrutide side effects are described most often?
Across all trial phases, gastrointestinal effects were reported most often: nausea, diarrhea, vomiting and constipation [1][2][4][5][6]. In TRIUMPH-2, diarrhea occurred in 27-34% of participants on retatrutide versus 13% on placebo, and nausea in 14-28% versus 8% [3]. The phase 2 authors described these events as mostly mild to moderate [1][2].
Do retatrutide side effects depend on the dose?
According to the trials, yes. In phase 2, gastrointestinal events were dose-related and partly reduced by a lower starting dose [1]. In TRIUMPH-2, nausea rose from 14% at 4 mg to 28% at 12 mg [3]. The dose schedules used in the trials are collected in a separate dosing reference, and this page does not recommend any of them.
Does retatrutide change heart rate?
In the phase 2 obesity trial the authors reported a dose-dependent increase in heart rate that peaked at week 24 and declined afterwards [1]. In TRIUMPH-2, hypotension was reported in 1-6% of participants on retatrutide versus under 1% on placebo [3]. These figures describe trial participants, not individual people.
Did the studies report dysesthesia?
Yes. In TRIUMPH-2, dysesthesia was reported in 4% of participants at 4 mg, 6% at 9 mg and 7% at 12 mg versus 1% on placebo [3]. The authors also singled out hypotension as an event that occurred more often on retatrutide [3]. The abstract reviewed does not describe how dysesthesia was recorded, so no further detail is available here.
What is known about products sold as retatrutide outside trials?
In this case report, the contents and dosing of the product claimed to be retatrutide were unconfirmed. Marked nausea followed several weekly injections; symptoms resolved within a week after admission with supportive care [8]. One case gives no frequency and does not establish retatrutide-specific causality. Trial data cannot automatically transfer to products of unconfirmed composition.
See also: all side-effects references, retatrutide monograph, product page.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. https://doi.org/10.1056/NEJMoa2301972
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. https://doi.org/10.1016/S0140-6736(23)01053-X
- Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. https://doi.org/10.1016/S0140-6736(26)01861-1
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. https://doi.org/10.1056/NEJMoa2604169
- Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413. https://doi.org/10.1016/S0140-6736(26)00967-0
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. https://doi.org/10.1016/S0140-6736(22)02033-5
- Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(3):291-303. https://doi.org/10.1080/08998280.2025.2456441
- Buzzi RM, Huber LC. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Rep. 2026;19(10):e276106. https://doi.org/10.1136/bcr-2026-276106